[go: up one dir, main page]

GB1554157A - Stable insulin preparation for intra nasal administration - Google Patents

Stable insulin preparation for intra nasal administration

Info

Publication number
GB1554157A
GB1554157A GB2535175A GB2535175A GB1554157A GB 1554157 A GB1554157 A GB 1554157A GB 2535175 A GB2535175 A GB 2535175A GB 2535175 A GB2535175 A GB 2535175A GB 1554157 A GB1554157 A GB 1554157A
Authority
GB
United Kingdom
Prior art keywords
nasal administration
insulin preparation
stable insulin
intra nasal
intra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2535175A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to GB2535175A priority Critical patent/GB1554157A/en
Priority to DE19762620483 priority patent/DE2620483A1/en
Priority to JP5493176A priority patent/JPS51148013A/en
Priority to FR7614706A priority patent/FR2313914A1/en
Priority to BE167069A priority patent/BE841870A/en
Priority to US05/824,955 priority patent/US4153689A/en
Publication of GB1554157A publication Critical patent/GB1554157A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB2535175A 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration Expired GB1554157A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GB2535175A GB1554157A (en) 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration
DE19762620483 DE2620483A1 (en) 1975-06-13 1976-05-08 STABLE AQUATIC INSULIN SOLUTIONS
JP5493176A JPS51148013A (en) 1975-06-13 1976-05-13 Stable insulin preparation for nosal administration
FR7614706A FR2313914A1 (en) 1975-06-13 1976-05-14 STABLE INSULIN PREPARATION FOR NASAL ADMINISTRATION
BE167069A BE841870A (en) 1975-06-13 1976-05-14 STABLE INSULIN PREPARATION
US05/824,955 US4153689A (en) 1975-06-13 1977-08-15 Stable insulin preparation for nasal administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2535175A GB1554157A (en) 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration

Publications (1)

Publication Number Publication Date
GB1554157A true GB1554157A (en) 1979-10-17

Family

ID=10226264

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2535175A Expired GB1554157A (en) 1975-06-13 1975-06-13 Stable insulin preparation for intra nasal administration

Country Status (5)

Country Link
JP (1) JPS51148013A (en)
BE (1) BE841870A (en)
DE (1) DE2620483A1 (en)
FR (1) FR2313914A1 (en)
GB (1) GB1554157A (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
EP0351651A2 (en) * 1988-07-21 1990-01-24 F. Hoffmann-La Roche Ag Insulin preparation
US5053389A (en) * 1986-04-18 1991-10-01 Per Balschmidt Insulin preparation for non-parenteral administration
US5693608A (en) * 1990-05-10 1997-12-02 Bechgaard International Research And Development A/S Method of administering a biologically active substance
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018609B1 (en) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
DE2917535C2 (en) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Insulin solutions resistant to denaturation
JPS58501125A (en) * 1981-07-17 1983-07-14 ノルデイスク・インスリンラボラトリウム Stable aqueous therapeutic insulin preparation and method for producing the same
DE3443877A1 (en) * 1984-06-09 1985-12-12 Hoechst Ag Insulin preparations, process for their preparation, and their use
JPS61267528A (en) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
EE9700138A (en) 1994-12-22 1997-12-15 Astra Aktiebolag Aerosol formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
ES2348303T3 (en) * 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS AND INSULIN TREATMENT PROCEDURES.
US7851419B2 (en) * 2005-09-12 2010-12-14 Nawaz Ahmad Substantially anhydrous sprayable personal lubricant
ITRM20110390A1 (en) * 2011-07-21 2013-01-22 Eramo Alessandra D PRODUCT TO STIMULATE THE ENDOGENOUS PRODUCTION OF INFLAMMATION MEDIATORS.
CA2920488C (en) * 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (en) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
US5053389A (en) * 1986-04-18 1991-10-01 Per Balschmidt Insulin preparation for non-parenteral administration
EP0351651A2 (en) * 1988-07-21 1990-01-24 F. Hoffmann-La Roche Ag Insulin preparation
EP0351651B1 (en) * 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulin preparation
US5693608A (en) * 1990-05-10 1997-12-02 Bechgaard International Research And Development A/S Method of administering a biologically active substance
AU687496B2 (en) * 1990-05-10 1998-02-26 Lyfjathroun HF., Biopharmaceuticals (Lyfjaproun) Nasal administration
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US12186374B2 (en) 2014-12-12 2025-01-07 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
BE841870A (en) 1976-11-16
DE2620483A1 (en) 1976-12-23
JPS51148013A (en) 1976-12-18
FR2313914A1 (en) 1977-01-07
FR2313914B1 (en) 1979-04-13

Similar Documents

Publication Publication Date Title
GB1554157A (en) Stable insulin preparation for intra nasal administration
NZ179733A (en) Stable insulin preparation
FR2321275A1 (en) INSULIN PREPARATION FOR NASAL ADMINISTRATION
GB1540882A (en) Medicament infuser units
PH23643A (en) Nasal pharmaceutical composition
ZA762920B (en) Novel pharmaceutical preparation adapted for oral administration
GB2014953B (en) Intravenous administration set
CS187429B2 (en) Inhalator for administering the powder medicines
PH12959A (en) Preparation of pharmaceutical unit dosage form
JPS5210415A (en) Anodyne for intraintestinal administration and its preparation
NZ179725A (en) Medicament dispensing inhalation device
NZ184060A (en) Sprayable pharmaceutical composition for topical administration
IL58209A0 (en) Medicament inhaler
ZA764868B (en) Novel pharmaceutical preparation adapted for oral administration
NZ180321A (en) Sustained release pharmaceutical preparation
GB1539076A (en) Process for preparing preparations for oral administration
IL51096A0 (en) Novel pharmaceutical dosage form
ZA764121B (en) Anesthetic delivery system
GB2014952B (en) Metering apparatus especially for use with an intravenous solution administration set
GB1549171A (en) Pharmaceutical formulations containing hydrocy bezophenonederivatives
GB2001076B (en) Psychopharmacological peptides suitable for therapeutic administration
AU8397675A (en) Insulin, analogs and derivatives thereof
JPS51133429A (en) Anesthetic composition
AU1333876A (en) Intravenous infusion set
IL47592A0 (en) Controlled drug releasing preparation

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee